Publication | Closed Access

Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study

MedicineMultiple Lines TreatmentPharmacologyImmunologyTherapeutic EfficacyImmune Checkpoint InhibitorPharmacotherapyAdvanced NsclcsImmunotherapyOncologyRadiation OncologyExpansion StudyNovel Therapy